GleamWall
中文EN

UPC Universe Pharmaceuticals INC Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1809616 · Fiscal year ends 09/30

Financial factors as of 2025-09-30 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-22.4%
TTM net income YoY57.9%
TTM EPS YoY98.7%
Revenue 3-yr CAGR663.4%
Net income 3-yr CAGR—

Margins

Gross margin35.3%
Operating margin-16.3%
Net margin-20.6%
FCF margin-29.8%
EBITDA margin-13.4%

Returns

ROE-7.2%
ROA-5.4%
ROIC (approx.)-12.0%
Asset turnover0.26x

Leverage & solvency

Liabilities / assets19.0%
Debt / equity0.00x
Current ratio4.07x
Interest coverage-10.08x

Cash quality & payout

Operating cash flow / net income1.38x
Accruals ratio2.0%
Payout ratio—
Capex / revenue1.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-09-30FY20242024-09-30
Income statement
Revenue$17.86B$23.02B
Cost of revenue$11.56B$16.95B
Gross profit$6.30B$6.07B
R&D expense$671.76M$3.03B
SG&A expense$3.75B$2.89B
Operating income-$2.92B-$8.02B
Interest expense$289.38M$304.52M
Pretax income-$3.67B-$8.12B
Income tax—$606.70M
Net income-$3.67B-$8.73B
EBITDA-$2.40B-$7.53B
EPS (basic)-8.06-626.96
EPS (diluted)-8.06-626.96
Weighted avg. shares (diluted)455,87113,920
Balance sheet
Cash & equivalents$33.59B$29.50B
Receivables$13.01B$12.91B
Inventory$2.19B$1.74B
Current assets$53.60B$51.64B
PP&E, net$3.58B$3.57B
Intangibles$296.79M$262.88M
Total assets$69.30B$67.95B
Current liabilities$13.17B$20.31B
Short-term debt$2.11B$5.86B
Total liabilities$13.17B$22.45B
Shareholders' equity$56.13B$45.50B
Shares outstanding563,33842,880
Cash flow statement
Operating cash flow-$5.05B-$9.51B
Capital expenditure$266.77M$208.32M
Free cash flow-$5.32B-$9.72B
Investing cash flow-$341.81M-$361.29M
Financing cash flow$9.73B$33.95B
Depreciation & amortization$517.43M$485.73M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.